| Date | Title | Description |
| 20.05.2025 | aTyr Pharma to Present at Upcoming Investor Conferences | SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today a... |
| 07.05.2025 | aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update | Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025.
Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology a... |
| 13.03.2025 | aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update | Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.
Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile.
Publica... |
| 13.03.2025 | aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update | Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.
Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile.
Publica... |
| 12.03.2025 | aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine | Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through neuropilin-2 (NRP2) receptor.
Scientific insights further strengthen the rationale for clinical program for efzofitimod in... |
| 07.11.2024 | aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update | Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025.
Publication in European Respiratory Journal demonstrated statistically significant difference in ti... |
| 31.10.2024 | aTyr Pharma to Present at Upcoming Investor Conferences | SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ... |
| 02.10.2024 | aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal | Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) gr... |
| 21.08.2024 | aTyr Pharma to Participate in September Investor Conferences | SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ... |
| 13.08.2024 | aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update | Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025.
Ended the second quarter 2024 with $81.4 million in cash, ca... |
| 13.08.2024 | aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update | Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025.
Ended the second quarter 2024 with $81.4 million in cash, ca... |
| 24.05.2024 | aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA sy... |
| 13.11.2023 | aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023 | Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company e... |
| 09.08.2023 | aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update | Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan.
Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the third quarter of 2023.
Ended the second qua... |
| 22.05.2023 | aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference | /EIN News/ -- Advancement in mechanistic understanding of efzofitimod’s modulation of myeloid cells to be featured in symposia presentation.
Exposure-efficacy data from Phase 1b/2a study of efzofitimod support efficacy across multiple clini... |
| 06.02.2023 | aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd. | /EIN News/ -- $10M milestone payment triggered by advancement of clinical program in Japan.
Multiple centers in the U.S. and Japan are now open for enrollment.
SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (a... |
| 18.11.2022 | aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | /EIN News/ -- SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today... |
| 25.10.2022 | aTyr Pharma to Present at the Jefferies London Healthcare Conference | SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced tha... |
| 25.10.2022 | aTyr Pharma to Present at the Jefferies London Healthcare Conference | /EIN News/ -- SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today... |
| 13.09.2022 | aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) | /EIN News/ -- Second Fast Track designation for efzofitimod clinical program.
Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc).
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:... |
| 13.09.2022 | aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) | Second Fast Track designation for efzofitimod clinical program.
Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc).
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clin... |
| 09.09.2022 | aTyr Pharma to Present at the Life Sciences Investor Forum on September 15th | SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, to... |
| 01.09.2022 | aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022 | SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced th... |
| 15.08.2022 | aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update | First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis.
FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis.
Ended the second quarter 2022 with $89.3 million in cash... |
| 11.08.2022 | aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis | SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA s... |
| 14.06.2022 | aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment | Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair.
Second tRNA synthetase receptor identified from company’s platform.
Findings suggest AARS fragment may have therapeutic potential in fibrosis, inflammation and c... |
| 13.06.2022 | aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference | SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today annou... |
| 01.06.2022 | aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference | SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced... |
| 16.05.2022 | aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis | Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022
Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LI... |
| 13.05.2022 | aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announ... |
| 09.05.2022 | aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update | Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May.
Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to ini... |
| 01.04.2022 | aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference | Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints.
Efzofitimod treatment reduces pro-inflammatory serum... |
| 23.02.2022 | aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day® | SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shu... |
| 07.02.2022 | aTyr Pharma to Present at BIO CEO & Investor Conference | SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shu... |
| 06.01.2022 | ATyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis | SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced tha... |
| 04.01.2022 | aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference | SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoo... |
| 24.12.2021 | ATyr Pharma Appoints Danielle Campbell as Vice President of Human Resources | SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of... |
| 10.12.2021 | ATyr Pharma to Present at Antibody Engineering & Therapeutics Conference | SAN DIEGO, Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a presentation at ... |
| 12.11.2021 | aTyr Pharma to Present at Upcoming Investor Conferences in November | SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shu... |
| 11.11.2021 | ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update - Form 8-K | aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA syn... |
| 11.11.2021 | ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update | Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target.
Registrational trial for ATYR1923 in ... |
| 10.11.2021 | aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update | Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target.
Registrational trial for ATYR1923 in ... |
| 09.11.2021 | ATyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting | Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance.
Data will support the clinical development of ATYR... |
| 06.10.2021 | aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs | SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of... |
| 06.10.2021 | ATyr Pharma : Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs | SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of... |
| 01.10.2021 | ATyr Pharma : Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting | SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company w... |
| 20.09.2021 | aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced th... |
| 16.09.2021 | ATyr Pharma : Announces Pricing of $75 Million Public Offering of Common Stock | SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced th... |
| 13.09.2021 | aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis | Trial met primary endpoint, ATYR1923 was safe and well-tolerated.
Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the group able to taper completely off of stero... |
| 13.09.2021 | ATyr Pharma : Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis (Form 8-K) | aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
Trial metprimary endpoint, ATYR1923 was safe and well-tolerated.
Efficacy observed in key endpo... |
| 10.08.2021 | ATyr Pharma : Announces Second Quarter 2021 Results and Provides Corporate Update | Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021.
Company to host conference call and webcast today, August 10th, at 5:00 p.m. EDT / 2:00 p.m. PDT.
SAN DIEGO, Aug. 10, 2021 (GLOBE NEWS... |
| 10.08.2021 | ATyr Pharma : Announces Second Quarter 2021 Results and Provides Corporate Update (Form 8-K) | aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021.
Company to host conference call and webcast today, Aug... |
| 10.08.2021 | ATyr Pharma : Announces Expansion of Research Collaboration with The Ohio State University | Collaboration led by Dr.
Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers.
SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clin... |
| 09.08.2021 | ATyr Pharma : Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress | SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts... |
| 29.07.2021 | ATyr Pharma : Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung | SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Pate... |
| 08.07.2021 | aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis | Results from proof-of-concept study are expected in September 2021.
SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines ba... |
| 23.06.2021 | ATyr Pharma : to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis | Event will feature Dr.
Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic.
Conference call and webcast scheduled for Tuesday June 29th at 5:00pm ET/2:00pm PT.
SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) -... |
| 10.06.2021 | ATYR PHARMA, INC.
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody | Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2.
aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in immune-mediated diseases.
SAN DIEGO, J... |
| 25.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen (Form 8-K) | aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen
SAN DIEGO - May 25, 2021 - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on... |
| 25.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen | SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of
... |
| 19.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810 | SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will presen... |
| 13.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Announces First Quarter 2021 Results and Provides Corporate Update | Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter.
Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC.
Bispecific antibody project with sub... |
| 13.05.2021 | ATyr Pharma : Announces First Quarter 2021 Results and Provides Corporate Update | Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter.
Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC.
Bispecific antibody project with sub... |
| 12.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform | SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company’s ... |
| 11.05.2021 | ATYR PHARMA, INC.
ATyr Pharma : Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research | SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the promotion of
Le... |
| 20.04.2021 | ATYR PHARMA, INC.
ATyr Pharma : and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Steroids and Sarcoidosis | SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and the Foundation for Sarcoidosi... |
| 15.04.2021 | ATYR PHARMA, INC.
ATyr Pharma : and Lonza Announce Manufacturing Agreement for aTyr's Anti-NRP2 Antibody ATYR2810 | Basel, Switzerland, and San Diego, USA - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the com... |
| 14.04.2021 | ATYR PHARMA, INC.
ATyr Pharma : and Lonza Announce Manufacturing Agreement for aTyr's Anti-NRP2 Antibody ATYR2810 | SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that th... |
| 08.04.2021 | ATYR PHARMA, INC.
aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor | SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment o... |
| 23.03.2021 | ATYR PHARMA, INC.
ATyr Pharma : Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update | Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter.
Results from ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications demonstrated favo... |
| 23.03.2021 | ATyr Pharma : Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update | Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter.
Results from ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications demonstrated favo... |
| 11.03.2021 | aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting | SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company ... |
| 10.03.2021 | Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor | SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment o... |
| 25.02.2021 | aTyr Pharma to Present at March Investor Conferences | SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will prese... |
| 21.11.2016 |
aTyr Pharma Gets $20M Credit Facility
| San Diego-based biotherapeutics developer aTyr Pharma announced this morning that it has received a $20M credit facility. The credit facility came from Silicon Valley Bank and Solar Capital Ltd. Terms of that credit facility were not announ... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 03.05.2015 | ATyr Pharma Plans to Raise Approximately $76M in IPO | ATyr Pharma Inc. is planning to raise approximately $76 million in an IPO May 7th. The company will issue 5,400,000 shares at a price of $13.00 to $15.00 per share.
The San Diego company, which was founded in 2005, plans to list on the Nasd... |
| 01.04.2015 | aTyr Pharma Completes $76M Series E Financing | aTyr Pharma, Inc., a San Diego, CA-based biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, completed a $76m Series E financing.
The round was led by new investors So... |
| 01.04.2015 | aTyr raised a $76M Series E. So when’s that IPO? | Another sign for pending IPO – large institutional investors.
The startup’s using the funding to advance its lead program, a physiocrine-based drug called Resolaris, through clinical trials. It’s being used in a Phase 1b/2 trial for patient... |
| 01.04.2015 | aTyr Pharma Secures $76M in Series E |
SAN DIEGO, CA, Biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, today announced the successful completion of a $76 million Series E financing.
>> Click her... |
| 01.04.2015 |
aTyr Pharma Finds $76M
| San Diego-based biopharmaceuticals developer aTyr Pharma has raised a big, $76M Series E funding round, the company said late Tuesday. According to aTyr, the funding as led by Sofinnova Ventures and an un-named, large institutional investor... |
| 31.03.2015 | aTyr Pharma Secures $76 Million in Series E Financing | |
| 29.07.2013 | aTyr Pharma Completes $49M Equity Financing | aTyr Pharma, a San Diego CA-based protein therapeutics enterprise focused on rare diseases, completed a $49m equity financing.
An undisclosed global public investment fund joined existing investors Alta Partners, Cardinal Partners, Domain A... |
| 29.07.2013 |
aTyr Pharma Gets $10M In Venture Debt
| San Diego-based aTyr Pharma, a developer of protein-based therapeutics, said today that it has raised $10M in a debt financing round. The funding came from Silicon Valley Bank. According to the company, the new funding will go towards clini... |
| 29.07.2013 | aTyr Pharma Completes $49 Million Financing to Advance a Therapeutic Pipeline for Rare Autoimmune Diseases from a Newly Discovered Class of Proteins, Physiocrines | |
| 29.07.2013 | aTyr Pharma Closes $10M Venture Debt |
SAN DIEGO, CA, Innovative protein therapeutics enterprise focused on rare diseases, announced today the close of $10 million debt financing from Silicon Valley Bank.
>> Click here for more funding data on aTyr Pharma
>> To e... |
| 29.07.2013 | aTyr Pharma Closes $10 Million Venture Debt Loan from Silicon Valley Bank | |
| 26.10.2010 |
aTyr Pharma Nabs $23M
| San Diego-based aTyr Pharma, a developer of biotherapeutics aimed at the blood, immune, and metabolism disorder areas, announced today that it has raised $23M in a Series C equity financing round. The round was led by Domain Associates, and... |
| 26.10.2010 | aTyr Pharma Raises $23M in Series C Financing | aTyr Pharma, a San Diego CA-based company that develops biologic therapeutics based on physiocrine, has raised $23m in Series C equity financing.
The round was led by Domain Associates, with participation from existing venture investors Alt... |
| 29.07.2009 | aTyr Pharma raises $12m for research | The company is discovering and developing biotherapeutics to treat a wide variety of diseases including inflammation, au |
| 28.07.2009 |
aTyr Pharma Gets $12M
| San Diego-based aTyr Pharma, which is developing biopharmaceuticals focused on inflammation, autoimmune, hematopoietic and metabolic disorders, disclosed Tuesday that it has raised $12M in an additional funding round. The firm said the fund... |
| 18.04.2007 |
aTyr Pharma Raises $10.5M
| San Diego-based aTyr Pharma, a biopharmaceutical firm focused on protein biologics for human therapeutics, said this morning that it has raised $10.5M in a Series B funding. The round was led by Alta Partners and Polaris Venture Partners. O... |
| - | aTyr raised a $76M Series E. So when’s that IPO? | San Diego biotech aTyr Pharma just closed out an impressive $76 million, with a large chunk of it purportedly raised by an undisclosed, large institutional investor and Soffinova Ventures.
Back at the JP Morgan conference in January, I hear... |
